Format

Send to

Choose Destination
Cancer Invest. 2001;19(1):23-7.

Malignant fibrous histiocytoma: an institutional review.

Author information

1
Division of Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York, USA. John.Gibbs@RoswellPark.org

Abstract

BACKGROUND:

A thorough understanding of malignant fibrous histiocytoma (MFH), the most common subtype of soft tissue sarcoma, will lead to improved histologic-specific protocols.

METHODS:

126 patients with histologically confirmed MFH were analyzed. The median follow-up was 42 months (range 1-233 months).

RESULTS:

Overall survival was 58% at 5 years and 38% at 10 years. Grade significantly influenced prognosis, with 10-year survival of 90%, 60%, and 20% for low, intermediate, and high grade tumors, respectively (p = 0.0007). Distant metastases at initial presentation (p = 0.0002) and size of the primary tumor (p = 0.0007) influenced outcome. Neither anatomic site nor depth of the primary tumor were significant prognostic factors. Positive microscopic margins were associated with a decreased disease-free survival (p = 0.006).

CONCLUSIONS:

Tumor grade, size, and distant metastases at initial presentation remain the most important prognostic factors for MFH. Resection with negative microscopic margins decreased the incidence of local recurrence.

PMID:
11291552
DOI:
10.1081/cnv-100000071
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center